Export 30 results:
Author [ Title(Asc)] Type Year
Filters: Author is Graham, Barney S  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
W
J. E. Ledgerwood, Pierson, T. C., Hubka, S. A., Desai, N., Rucker, S., Gordon, I. J., Enama, M. E., Nelson, S., Nason, M., Gu, W., Bundrant, N., Koup, R. A., Bailer, R. T., Mascola, J. R., Nabel, G. J., and Graham, B. S., “A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.”, J Infect Dis, vol. 203, no. 10, pp. 1396-404, 2011.
T
J. P. Casazza, Bowman, K. A., Adzaku, S., Smith, E. C., Enama, M. E., Bailer, R. T., Price, D. A., Gostick, E., Gordon, I. J., Ambrozak, D. R., Nason, M. C., Roederer, M., Andrews, C. A., Maldarelli, F. M., Wiegand, A., Kearney, M. F., Persaud, D., Ziemniak, C., Gottardo, R., Ledgerwood, J. E., Graham, B. S., and Koup, R. A., “Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.”, J Infect Dis, vol. 207, no. 12, pp. 1829-40, 2013.
S
J. E. Martin, Louder, M. K., Holman, L. S. A., Gordon, I. J., Enama, M. E., Larkin, B. D., Andrews, C. A., Vogel, L., Koup, R. A., Roederer, M., Bailer, R. T., Gomez, P. L., Nason, M., Mascola, J. R., Nabel, G. J., and Graham, B. S., “A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.”, Vaccine, vol. 26, no. 50, pp. 6338-43, 2008.
J. Parrino, McCurdy, L. H., Larkin, B. D., Gordon, I. J., Rucker, S. E., Enama, M. E., Koup, R. A., Roederer, M., Bailer, R. T., Moodie, Z., Gu, L., Yan, L., and Graham, B. S., “Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.”, Vaccine, vol. 25, no. 8, pp. 1513-25, 2007.
L. - J. Chang, Dowd, K. A., Mendoza, F. H., Saunders, J. G., Sitar, S., Plummer, S. H., Yamshchikov, G., Sarwar, U. N., Hu, Z., Enama, M. E., Bailer, R. T., Koup, R. A., Schwartz, R. M., Akahata, W., Nabel, G. J., Mascola, J. R., Pierson, T. C., Graham, B. S., and Ledgerwood, J. E., “Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.”, Lancet, vol. 384, no. 9959, pp. 2046-52, 2014.
W. Jaoko, Karita, E., Kayitenkore, K., Omosa-Manyonyi, G., Allen, S., Than, S., Adams, E. M., Graham, B. S., Koup, R. A., Bailer, R. T., Smith, C., Dally, L., Farah, B., Anzala, O., Muvunyi, C. M., Bizimana, J., Tarragona-Fiol, T., Bergin, P. J., Hayes, P., Ho, M., Loughran, K., Komaroff, W., Stevens, G., Thomson, H., Boaz, M. J., Cox, J. H., Schmidt, C., Gilmour, J., Nabel, G. J., Fast, P., and Bwayo, J., “Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.”, PLoS One, vol. 5, no. 9, p. e12873, 2010.
E. J. Anderson, Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., McDermott, A. B., Flach, B., Lin, B. C., Doria-Rose, N. A., O'Dell, S., Schmidt, S. D., Corbett, K. S., Swanson, P. A., Padilla, M., Neuzil, K. M., Bennett, H., Leav, B., Makowski, M., Albert, J., Cross, K., Edara, V. Viswanadh, Floyd, K., Suthar, M. S., Martinez, D. R., Baric, R., Buchanan, W., Luke, C. J., Phadke, V. K., Rostad, C. A., Ledgerwood, J. E., Graham, B. S., and Beigel, J. H., “Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.”, N Engl J Med, 2020.
C. Carter, Houser, K. V., Yamshchikov, G. V., Bellamy, A. R., May, J., Enama, M. E., Sarwar, U., Larkin, B., Bailer, R. T., Koup, R., Chen, G. L., Patel, S. M., Winokur, P., Belshe, R., Dekker, C. L., Graham, B. S., and Ledgerwood, J. E., “Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.”, PLoS One, vol. 14, no. 9, p. e0222178, 2019.
H. Kibuuka, Berkowitz, N. M., Millard, M., Enama, M. E., Tindikahwa, A., Sekiziyivu, A. B., Costner, P., Sitar, S., Glover, D., Hu, Z., Joshi, G., Stanley, D., Kunchai, M., Eller, L. Anne, Bailer, R. T., Koup, R. A., Nabel, G. J., Mascola, J. R., Sullivan, N. J., Graham, B. S., Roederer, M., Michael, N. L., Robb, M. L., and Ledgerwood, J. E., “Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.”, Lancet, vol. 385, no. 9977, pp. 1545-54, 2015.
U. N. Sarwar, Costner, P., Enama, M. E., Berkowitz, N., Hu, Z., Hendel, C. S., Sitar, S., Plummer, S., Mulangu, S., Bailer, R. T., Koup, R. A., Mascola, J. R., Nabel, G. J., Sullivan, N. J., Graham, B. S., and Ledgerwood, J. E., “Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial.”, J Infect Dis, vol. 211, no. 4, pp. 549-57, 2015.
T. A. Crowell, Colby, D. J., Pinyakorn, S., Sacdalan, C., Pagliuzza, A., Intasan, J., Benjapornpong, K., Tangnaree, K., Chomchey, N., Kroon, E., de Souza, M. S., Tovanabutra, S., Rolland, M., Eller, M. A., Paquin-Proulx, D., Bolton, D. L., Tokarev, A., Thomas, R., Takata, H., Trautmann, L., Krebs, S. J., Modjarrad, K., McDermott, A. B., Bailer, R. T., Doria-Rose, N., Patel, B., Gorelick, R. J., Fullmer, B. A., Schuetz, A., Grandin, P. V., O'Connell, R. J., Ledgerwood, J. E., Graham, B. S., Tressler, R., Mascola, J. R., Chomont, N., Michael, N. L., Robb, M. L., Phanuphak, N., and Ananworanich, J., “Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.”, Lancet HIV, vol. 6, no. 5, pp. e297-e306, 2019.
P
R. A. Seder, Chang, L. - J., Enama, M. E., Zephir, K. L., Sarwar, U. N., Gordon, I. J., Holman, L. S. A., James, E. R., Billingsley, P. F., Gunasekera, A., Richman, A., Chakravarty, S., Manoj, A., Velmurugan, S., Li, M. L., Ruben, A. J., Li, T., Eappen, A. G., Stafford, R. E., Plummer, S. H., Hendel, C. S., Novik, L., Costner, P. J. M., Mendoza, F. H., Saunders, J. G., Nason, M. C., Richardson, J. H., Murphy, J., Davidson, S. A., Richie, T. L., Sedegah, M., Sutamihardja, A., Fahle, G. A., Lyke, K. E., Laurens, M. B., Roederer, M., Tewari, K., Epstein, J. E., B Sim, K. Lee, Ledgerwood, J. E., Graham, B. S., and Hoffman, S. L., “Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine.”, Science, vol. 341, no. 6152, pp. 1359-65, 2013.
R. A. Koup, Roederer, M., Lamoreaux, L., Fischer, J., Novik, L., Nason, M. C., Larkin, B. D., Enama, M. E., Ledgerwood, J. E., Bailer, R. T., Mascola, J. R., Nabel, G. J., and Graham, B. S., “Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.”, PLoS One, vol. 5, no. 2, p. e9015, 2010.
J. E. Ledgerwood, Zephir, K., Hu, Z., Wei, C. - J., Chang, L., Enama, M. E., Hendel, C. S., Sitar, S., Bailer, R. T., Koup, R. A., Mascola, J. R., Nabel, G. J., and Graham, B. S., “Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect.”, J Infect Dis, vol. 208, no. 3, pp. 418-22, 2013.
M. E. Enama, Ledgerwood, J. E., Novik, L., Nason, M. C., Gordon, I. J., Holman, L. S., Bailer, R. T., Roederer, M., Koup, R. A., Mascola, J. R., Nabel, G. J., and Graham, B. S., “Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011).”, PLoS One, vol. 9, no. 3, p. e91366, 2014.
A. T. Catanzaro, Roederer, M., Koup, R. A., Bailer, R. T., Enama, M. E., Nason, M. C., Martin, J. E., Rucker, S., Andrews, C. A., Gomez, P. L., Mascola, J. R., Nabel, G. J., and Graham, B. S., “Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.”, Vaccine, vol. 25, no. 20, pp. 4085-92, 2007.
M. C. Crank, Gordon, I. J., Yamshchikov, G. V., Sitar, S., Hu, Z., Enama, M. E., Holman, L. S. A., Bailer, R. T., Pearce, M. B., Koup, R. A., Mascola, J. R., Nabel, G. J., Tumpey, T. M., Schwartz, R. M., Graham, B. S., and Ledgerwood, J. E., “Phase 1 study of pandemic H1 DNA vaccine in healthy adults.”, PLoS One, vol. 10, no. 4, p. e0123969, 2015.
B. S. Graham, Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Martin, J. E., McCluskey, M. M., Chakrabarti, B. K., Lamoreaux, L., Andrews, C. A., Gomez, P. L., Mascola, J. R., and Nabel, G. J., “Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.”, J Infect Dis, vol. 194, no. 12, pp. 1650-60, 2006.
A. T. Catanzaro, Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Gu, L., Martin, J. E., Novik, L., Chakrabarti, B. K., Butman, B. T., Gall, J. G. D., C King, R., Andrews, C. A., Sheets, R., Gomez, P. L., Mascola, J. R., Nabel, G. J., and Graham, B. S., “Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.”, J Infect Dis, vol. 194, no. 12, pp. 1638-49, 2006.
M
L. A. Jackson, Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., McDermott, A., Flach, B., Doria-Rose, N. A., Corbett, K. S., Morabito, K. M., O'Dell, S., Schmidt, S. D., Swanson, P. A., Padilla, M., Mascola, J. R., Neuzil, K. M., Bennett, H., Sun, W., Peters, E., Makowski, M., Albert, J., Cross, K., Buchanan, W., Pikaart-Tautges, R., Ledgerwood, J. E., Graham, B. S., and Beigel, J. H., “An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.”, N Engl J Med, 2020.
I
B. S. Graham, M McElrath, J., Keefer, M. C., Rybczyk, K., Berger, D., Weinhold, K. J., Ottinger, J., Ferarri, G., Montefiori, D. C., Stablein, D., Smith, C., Ginsberg, R., Eldridge, J., Duerr, A., Fast, P., and Haynes, B. F., “Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.”, PLoS One, vol. 5, no. 8, p. e11995, 2010.
H
U. N. Sarwar, Novik, L., Enama, M. E., Plummer, S. A., Koup, R. A., Nason, M. C., Bailer, R. T., McDermott, A. B., Roederer, M., Mascola, J. R., Ledgerwood, J. E., and Graham, B. S., “Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.”, PLoS One, vol. 9, no. 9, p. e106240, 2014.
D
A. Pegu, O'Connell, S. E., Schmidt, S. D., O'Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., Flach, B., Jackson, L., Leav, B., Ledgerwood, J. E., Luke, C. J., Makowski, M., Nason, M. C., Roberts, P. C., Roederer, M., Rebolledo, P. A., Rostad, C. A., Rouphael, N. G., Shi, W., Wang, L., Widge, A. T., Yang, E. Sung, Beigel, J. H., Graham, B. S., Mascola, J. R., Suthar, M. S., McDermott, A. B., Doria-Rose, N. A., Arega, J., Beigel, J. H., Buchanan, W., Elsafy, M., Hoang, B., Lampley, R., Kolhekar, A., Koo, H., Luke, C., Makhene, M., Nayak, S., Pikaart-Tautges, R., Roberts, P. C., Russell, J., Sindall, E., Albert, J., Kunwar, P., Makowski, M., Anderson, E. J., Bechnak, A., Bower, M., Camacho-Gonzalez, A. F., Collins, M., Drobeniuc, A., Edara, V. Viswanadh, Edupuganti, S., Floyd, K., Gibson, T., Ackerley, C. M. Grimsley, Johnson, B., Kamidani, S., Kao, C., Kelley, C., Lai, L., Macenczak, H., McCullough, M. Paine, Peters, E., Phadke, V. K., Rebolledo, P. A., Rostad, C. A., Rouphael, N., Scherer, E., Sherman, A., Stephens, K., Suthar, M. S., Teherani, M., Traenkner, J., Winston, J., Yildirim, I., Barr, L., Benoit, J., Carste, B., Choe, J., Dunstan, M., Erolin, R., Ffitch, J., Fields, C., Jackson, L. A., Kiniry, E., Lasicka, S., Lee, S., Nguyen, M., Pimienta, S., Suyehira, J., Witte, M., Bennett, H., Altaras, N. Emil, Carfi, A., Hurley, M., Leav, B., Pajon, R., Sun, W., Zaks, T., Coler, R. N., Larsen, S. E., Neuzil, K. M., Lindesmith, L. C., Martinez, D. R., Munt, J., Mallory, M., Edwards, C., Baric, R. S., Berkowitz, N. M., Boritz, E. A., Carlton, K., Corbett, K. S., Costner, P., Creanga, A., Doria-Rose, N. A., Douek, D. C., Flach, B., Gaudinski, M., Gordon, I., Graham, B. S., Holman, L. S., Ledgerwood, J. E., Leung, K., Lin, B. C., Louder, M. K., Mascola, J. R., McDermott, A. B., Morabito, K. M., Novik, L., O'Connell, S., O'Dell, S., Padilla, M., Pegu, A., Schmidt, S. D., Shi, W., Swanson, P. A., Talana, C. A., Wang, L., Widge, A. T., Yang, E. Sung, Zhang, Y., Chappell, J. D., Denison, M. R., Hughes, T., Lu, X., Pruijssers, A. J., Stevens, L. J., Posavad, C. M., Gale, M., Menachery, V., and Shi, P. - Y., “Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.”, Science, vol. 373, no. 6561, pp. 1372-1377, 2021.
A. Pegu, O'Connell, S. E., Schmidt, S. D., O'Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., Flach, B., Jackson, L., Leav, B., Ledgerwood, J. E., Luke, C. J., Makowski, M., Nason, M. C., Roberts, P. C., Roederer, M., Rebolledo, P. A., Rostad, C. A., Rouphael, N. G., Shi, W., Wang, L., Widge, A. T., Yang, E. Sung, Beigel, J. H., Graham, B. S., Mascola, J. R., Suthar, M. S., McDermott, A. B., Doria-Rose, N. A., Arega, J., Beigel, J. H., Buchanan, W., Elsafy, M., Hoang, B., Lampley, R., Kolhekar, A., Koo, H., Luke, C., Makhene, M., Nayak, S., Pikaart-Tautges, R., Roberts, P. C., Russell, J., Sindall, E., Albert, J., Kunwar, P., Makowski, M., Anderson, E. J., Bechnak, A., Bower, M., Camacho-Gonzalez, A. F., Collins, M., Drobeniuc, A., Edara, V. Viswanadh, Edupuganti, S., Floyd, K., Gibson, T., Ackerley, C. M. Grimsley, Johnson, B., Kamidani, S., Kao, C., Kelley, C., Lai, L., Macenczak, H., McCullough, M. Paine, Peters, E., Phadke, V. K., Rebolledo, P. A., Rostad, C. A., Rouphael, N., Scherer, E., Sherman, A., Stephens, K., Suthar, M. S., Teherani, M., Traenkner, J., Winston, J., Yildirim, I., Barr, L., Benoit, J., Carste, B., Choe, J., Dunstan, M., Erolin, R., Ffitch, J., Fields, C., Jackson, L. A., Kiniry, E., Lasicka, S., Lee, S., Nguyen, M., Pimienta, S., Suyehira, J., Witte, M., Bennett, H., Altaras, N. Emil, Carfi, A., Hurley, M., Leav, B., Pajon, R., Sun, W., Zaks, T., Coler, R. N., Larsen, S. E., Neuzil, K. M., Lindesmith, L. C., Martinez, D. R., Munt, J., Mallory, M., Edwards, C., Baric, R. S., Berkowitz, N. M., Boritz, E. A., Carlton, K., Corbett, K. S., Costner, P., Creanga, A., Doria-Rose, N. A., Douek, D. C., Flach, B., Gaudinski, M., Gordon, I., Graham, B. S., Holman, L. S., Ledgerwood, J. E., Leung, K., Lin, B. C., Louder, M. K., Mascola, J. R., McDermott, A. B., Morabito, K. M., Novik, L., O'Connell, S., O'Dell, S., Padilla, M., Pegu, A., Schmidt, S. D., Shi, W., Swanson, P. A., Talana, C. A., Wang, L., Widge, A. T., Yang, E. Sung, Zhang, Y., Chappell, J. D., Denison, M. R., Hughes, T., Lu, X., Pruijssers, A. J., Stevens, L. J., Posavad, C. M., Gale, M., Menachery, V., and Shi, P. - Y., “Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.”, Science, vol. 373, no. 6561, pp. 1372-1377, 2021.
K. V. Houser, Yamshchikov, G. V., Bellamy, A. R., May, J., Enama, M. E., Sarwar, U., Larkin, B., Bailer, R. T., Koup, R., Paskel, M., Subbarao, K., Anderson, E., Bernstein, D. I., Creech, B., Keyserling, H., Spearman, P., Wright, P. F., Graham, B. S., and Ledgerwood, J. E., “DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial.”, PLoS One, vol. 13, no. 11, p. e0206837, 2018.